C
Concertobio
Reinventing humanity's relationship with microbes with advanced microbial interaction screening technology
About Concertobio
Concerto Bio is a biotech startup that operates in the field of microbial research. The company's primary focus is on discovering and developing innovative microbial, prebiotic, and postbiotic products. These products are derived from the study of complex microbial relationships, which hold the potential for groundbreaking discoveries.
The company's clients are primarily other biotech and biopharma companies. Concerto Bio partners with these companies, combining their respective capabilities to create transformative products. This collaborative approach allows Concerto Bio to leverage the expertise of its partners while also contributing its unique insights and technology.
The company's business model revolves around its proprietary kChip discovery engine. This technology allows Concerto Bio to construct millions of miniature, defined microbial communities simultaneously. By analyzing the behavior of each community, the company can identify the microbes, nutrients, and metabolites that drive the functions required for the best product candidates. This rigorous experimental approach sets Concerto Bio apart in the field of microbial product discovery.
Concerto Bio generates revenue through its partnerships with other biotech and biopharma companies. These partnerships involve the joint development of microbial products, with Concerto Bio providing its unique technology and expertise. The company's location in Cambridge, MA, places it at the heart of one of the world's leading biotech hubs, providing ample opportunities for collaboration and growth.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 60.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2022 | $23M | $92M | Horizons Ventures · Safar Partners · M Ventures | ↗ |
| SERIES AEquity / VC | Mar 2022 | $25M | $98M | M Ventures · Safar Partners · Horizons Ventures | ↗ |
Growth signals
Latest recorded traffic for Concertobio is 2.5K monthly website visits, down 7.4% over the last three months. Concertobio's team declined 27.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Safar Partners
M Ventures
Horizons Ventures
Other known investors8 additional known investors
Massachusetts Institute of Technology
Alumni Ventures
Axial VC
Endless Frontier Labs
Impact Science Ventures
MassVentures
Skylight Investment
Taihill Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Concertobio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Concertobio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







